Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$134.28
$0.02(0.01%)
At close: 4:00 PM EDT
$134.28
$0.02(0.01%)
Day’s Range― - ―
52-Week Range$35.39 - $134.88
Previous CloseN/A
Volume558.23K
Average Volume (3M)4.35M
Market Cap
$10.18B
Enterprise Value$9.15K
Total Cash (Recent Filing)$971.93M
Total Debt (Recent Filing)$6.83M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 16, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding62,201,090
10 Day Avg. Volume1,022,216
30 Day Avg. Volume4,345,940
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$131.18Price Target Upside-2.31% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-4.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Capital BaseExtremely low debt relative to equity and sizable assets give Apogee durable financial flexibility to fund late-stage trials and development timelines. This reduces near-term dilution risk, supports multi-year R&D spending, and improves ability to negotiate partnerships or withstand trial timelines without urgent financing.
AbbVie All-cash Acquisition AgreementA signed all-cash merger with AbbVie represents a structural change and validation of Apogee’s pipeline, materially de-risking shareholder outcomes and accelerating commercialization access for assets. If cleared, it converts R&D value into cash and aligns Apogee assets with AbbVie’s commercialization scale and regulatory resources.
Positive Phase 2 Results And Explicit Late-stage RoadmapRobust Phase 2 efficacy and a defined Phase 3/expansion plan materially raise the probability of a successful registrational pathway. The long-acting dosing profile and multi-indication planning (AD, asthma, EoE) strengthen potential market differentiation and long-term commercial upside across high-value immunology indications.
Bears Say
Rising And Substantial Cash BurnOperating cash outflows have accelerated sharply as development scaled, creating ongoing funding dependence. Large negative free cash flow implies the company must secure significant capital or complete strategic transactions to sustain late-stage programs; failure or delays in financing would threaten program timelines and execution.
Minimal Revenue And Widening Net LossesAs a pre-commercial biotech with negligible revenue and sharply increasing losses, Apogee lacks operating leverage and a near-term path to profitability. Persistent negative returns on equity reflect capital consumption and heighten reliance on clinical success and external funding to eventually generate sustainable cash flows.
Long-term Royalty Financing Constrains Future MarginsThe non-dilutive Blackstone structure provides near-term capital but commits a portion of future sales to revenue share for 15 years, reducing long-term gross-to-net economics. This durable obligation could materially lower margins, constrain reinvestment capacity, and affect pricing/partnering flexibility post-approval.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $35.39 and its highest was $134.88 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Apogee Therapeutics, Inc.’s market cap is $10.18B.
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 93 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on Aug 10, 2026. The company reported -$1.14 earnings per share for the quarter, missing the consensus estimate of -$1.072 by -$0.068.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Overvalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -1.15.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 62,201,090 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$1.14 in its last earnings report, missing expectations of -$1.072. Following the earnings report the stock price went down -0.141%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$131.18 (-2.31% Downside)
$131.18 (-2.31% Downside)
Blogger Sentiment
Neutral
APGE Sentiment 75%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
228.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
103.08%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$131.18
▼(-2.31% Downside)
Technical Analysis
Ownership Overview
5.56% Insiders
39.36% Mutual Funds
7.48% Other Institutional Investors
33.87% Public Companies and
Individual Investors